Pharmacokinetics and toxicity of methotrexate in children with Down syndrome and acute lymphocytic leukemia

The Journal of Pediatrics

Volumn 111, Issue 4, 1987, Pages 606-612

  Garré, Maria Luisa ^a,b,c   Relling, Mary V ^a,b,c   Kalwinsky, David ^a,b,c   Dodge, Richard ^a,b,c   Crom, William R ^a,b,c   Abromowitch, Minnie ^a,b,c   Pui, Ching Hon ^a,b,c   Evans, William E ^a,b,c  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b Department of Hematology Oncology St Jude Children's Research Hospital ^*  (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOLINIC ACID; METHOTREXATE;

ACUTE LYMPHOCYTIC LEUKEMIA; ADVERSE DRUG REACTION; BLOOD AND HEMOPOIETIC SYSTEM; CHILD; CLINICAL ARTICLE; CONGENITAL DISORDER; CONTROLLED STUDY; DOWN SYNDROME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG TOLERANCE; DRUG TOXICITY; GASTROINTESTINAL TOXICITY; HEREDITY; HUMAN; INTOXICATION; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; THERAPY;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DOWN SYNDROME; HUMANS; LEUCOVORIN; LEUKEMIA, LYMPHOCYTIC; METHOTREXATE;

EID: 0023200576     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-3476(87)80131-2     Document Type: Article

References (36)

1. Down syndrome and acute leukemia in children: a 10-year retrospective survey from Childrens Cancer Study Group
2. Excessive drug toxicity in children with Down's syndrome (DS) treated for acute lymphocytic leukemia (ALL) despite similarity of clinical and biological features to other patients
3. Acute lymphocytic leukemia (ALL) in children with Down's syndrome
4. Excessive chemotherapy-related myelotoxicity in children with Down syndrome and acute lymphyoblastic leukemia
5. Recovery from toxicity associated with high-dose methotrexate: prognostic factors
6. Hyper-reactivity to atropine in Down's syndrome
7. Thiabendazole-associated grand mal seizures in a patient with Down syndrome
8. Alteration in metabolism of acetylsalicylic acid in children with Down's syndrome: decreased plasma binding and formation of salicyluric acid
9. Thyroid dysfunction in Down syndrome
10. Renal impairment in urate excretion in patients with Down's syndrome
11. Down syndrome: a review of recent progress in research
12. Alzheimer's disease, trisomy 21, and myeloproliferative disorders: associations suggesting a genetic diathesis
13. St. Jude Total Therapy Study X for standard-risk acute lymphocytic leukemia (ALL): 4-year follow-up
14. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia
15. Evaluation of toxicity: clinical issues
16. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine
17. Prediction of creatinine clearance from serum creatinine
18. Evaluation of enzyme immunoassay, radioassay, and radioimmunoassay of serum methotrexate, as compared with liquid chromatography
19. Pharmacokinetic monitoring of high-dose methotrexate
20. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity
21. High dose methotrexate with CF rescue: predictive value of serum methotrexate concentrations and corrective measures to avert toxicity
22. Pharmacokinetics of high-dose methotrexate with citrovorum factor rescue
23. Renal function and the rate of disappearance of methotrexate from serum
24. A survey of serum uric acid levels in mentally retarded patients
25. Clearance of uric acid, urea, and creatinine in Down's syndrome
26. Regulation of methotrexate polyglutaminate formation in Ehrlich ascites carcinoma cells by endogenous folate pool
27. Evidence for the cytotoxic activity of polyglutamate derivatives of methotrexate
28. 5 to dihydrofolate reductase
29. Synthesis, retention, and biological activity of methotrexate polyglutamates in cultured human breast cancer cells
30. Prolonged inhibition of DNA synthesis associated with the accumulation of methotrexate polyglutamates by cultured human cells
31. The influence of extracellular folate concentration on methotrexate uptake by human KB cells
32. Leucocyte ultrastructure and folate metabolism in Down's syndrome
33. Folates in biological materials
34. Toxicity of leukaemia therapy in children with Down syndrome
35. Metabolisme des monocarbones et trisomie 21: sensibilite au methotrexate